These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17611218)

  • 41. Chemotherapy-induced cardiotoxicity in women.
    Dempsey KS
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trastuzumab and cardiotoxicity: weighing the risks.
    Wong SF
    Am J Health Syst Pharm; 2006 Mar; 63(6):525. PubMed ID: 16522888
    [No Abstract]   [Full Text] [Related]  

  • 43. Lack of uniformity in cardiac assessment during trastuzumab therapy.
    Subar M; Lin W; Chen W; Pittman DG
    Breast J; 2011; 17(4):383-90. PubMed ID: 21615821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Learn to assess for and manage trastuzumab-induced cardiotoxicity.
    Becze E
    ONS Connect; 2009 Dec; 24(12):12-3. PubMed ID: 20039567
    [No Abstract]   [Full Text] [Related]  

  • 45. Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
    Milano G; Chamorey E; Ferrero JM
    JAMA Oncol; 2016 Jan; 2(1):21-2. PubMed ID: 26540493
    [No Abstract]   [Full Text] [Related]  

  • 46. Trastuzamab (Herceptin)-related cardiotoxicity in pregnancy.
    Roberts NJ; Auld BJ
    J R Soc Med; 2010 Apr; 103(4):157-9. PubMed ID: 20382907
    [No Abstract]   [Full Text] [Related]  

  • 47. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
    van Hasselt JG; Boekhout AH; Beijnen JH; Schellens JH; Huitema AD
    Clin Pharmacol Ther; 2011 Jul; 90(1):126-32. PubMed ID: 21633346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
    Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
    Ewer MS; Lenihan DJ
    J Clin Oncol; 2008 Mar; 26(8):1201-3. PubMed ID: 18227525
    [No Abstract]   [Full Text] [Related]  

  • 50. HER2-positive breast cancer: current treatment strategies.
    Perez EA; Baweja M
    Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
    [No Abstract]   [Full Text] [Related]  

  • 51. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 52. Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent?
    Brann AM; Cobleigh MA; Okwuosa TM
    JAMA Oncol; 2016 Sep; 2(9):1123-4. PubMed ID: 27280310
    [No Abstract]   [Full Text] [Related]  

  • 53. Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review.
    Tu CM; Chu KM; Yang SP; Cheng SM; Wang WB
    Am J Emerg Med; 2009 Sep; 27(7):903.e1-3. PubMed ID: 19683138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
    Ewer MS; Tan-Chiu E
    J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
    [No Abstract]   [Full Text] [Related]  

  • 55. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
    Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trastuzumab and breast cancer.
    Palmieri C; Powles T; Vigushin D
    N Engl J Med; 2001 Sep; 345(13):996-7. PubMed ID: 11575297
    [No Abstract]   [Full Text] [Related]  

  • 57. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
    Morris PG; Chen C; Steingart R; Fleisher M; Lin N; Moy B; Come S; Sugarman S; Abbruzzi A; Lehman R; Patil S; Dickler M; McArthur HL; Winer E; Norton L; Hudis CA; Dang CT
    Clin Cancer Res; 2011 May; 17(10):3490-9. PubMed ID: 21372222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-dense chemotherapy with trastuzumab is an appropriate option.
    Dang C; Norton L; Hudis C
    J Clin Oncol; 2008 Jul; 26(21):3655-6; author reply 3656. PubMed ID: 18640949
    [No Abstract]   [Full Text] [Related]  

  • 59. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
    Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
    J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients].
    Zhou NN; Teng XY; Liu DG; Xu R; Guan ZZ
    Ai Zheng; 2008 Dec; 27(12):1307-9. PubMed ID: 19079999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.